
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is projected to report revenues of $315.0 million, reflecting a 3% increase compared to the previous quarter, indicating consistent growth in its operations. The adjusted earnings per share are anticipated to reach $0.50, which represents a year-over-year improvement from $0.49, suggesting solid financial performance in the face of market conditions. The company's strong foothold in the life sciences sector, particularly within its protein sciences segment, underpins a positive outlook for sustained revenue and earnings growth moving forward.
Bears say
Bio-Techne faces a challenging outlook due to the anticipated escalation of U.S. tariffs and proposed cuts in funding for U.S. agencies, including the NIH, which are likely to adversely affect revenue and gross margins for the fourth quarter of 2025. The firm is adjusting its estimates for that quarter, indicating expectations of slower-than-anticipated revenue and margin performance. The concentrated impact of these external economic factors on approximately 75% of its revenue from the protein sciences segment raises fundamental concerns regarding ongoing financial stability.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares